Last reviewed · How we verify
Placebo via DISKUS / ACCUHALER
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials and research.
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials and research. Used for Clinical trial control / research use only.
At a glance
| Generic name | Placebo via DISKUS / ACCUHALER |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is a non-therapeutic agent administered in identical form to active drugs for comparison purposes in blinded clinical studies. Any observed effects are attributable to the placebo effect—psychological and physiological responses to the expectation of treatment rather than to a specific molecular mechanism. The DISKUS and ACCUHALER are dry powder inhalation devices used to deliver placebo or active respiratory medications.
Approved indications
- Clinical trial control / research use only
Common side effects
Key clinical trials
- Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB) (PHASE4)
- An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma (PHASE3)
- A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo via DISKUS / ACCUHALER CI brief — competitive landscape report
- Placebo via DISKUS / ACCUHALER updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI